WELLESLEY HILLS, Mass. — August 25, 2025 — Leads & Copy — Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, announced its executive team will participate in upcoming investor conferences.
The conferences include the Cantor Global Healthcare Conference (Sept. 5, New York), the Baird Global Healthcare Conference (Sept. 9, New York), the Morgan Stanley Annual Global Healthcare Conference (Sept. 10, New York), and the Stifel Virtual Immunology and Inflammation Forum (Sept. 10, Virtual).
Live webcasts will be accessible via the “Investors and News” section of the Climb Bio website. Webcast replays will be available on the Climb Bio website beginning approximately two hours after each webcast event and will be archived for at least 30 days.
Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy.
Carlo Tanzi, Ph.D., of Kendall Investor Relations, can be reached at ctanzi@kendallir.com.
Source: Climb Bio, Inc.
